A prospective Longitudinal trial of the effect of Atomoxetine on cognitive, educational, behavioural, social and emotional wellbeing in students with Attention Deficit Hyperactivity Disorder

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN05214203

Enrollment

144

Registered

2006-11-20

Start date

2006-11-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention Deficit Hyperactivity Disorder Mental and Behavioural Disorders Behavioural and emotional disorders

Interventions

Administration of atomoxetine for 26 weeks.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Boys and girls aged seven to 15 years 2. Meet the Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition (DSM-IV) criteria for ADHD, as determined by the referring paediatrician or child psychiatrist 3. Participants are naive to atomoxetine medication

Exclusion criteria

Exclusion criteria: 1. A history of bipolar or psychotic disorder 2. Tourette?s syndrome 3. Substance abuse 4. Serious medical illness 5. Intellectual disability (Intelligence Quotient [IQ] less than 70) 6. Pregnancy 7. Non compliance with research protocol

Design outcomes

Primary

Measure	Time frame
1. Cognitive functioning, working memory, verbal ability and cognitive efficiency 2. Executive functioning (teacher and parent ratings) 3. Educational achievement	—

Secondary

Measure	Time frame
1. Depression (child, parent, teacher ratings) 2. Anxiety (child and parent ratings) 3. Social skills (teacher and parent ratings) 4. Perceptions of learning environment (child ratings)	—

Countries

Australia

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026